124 related articles for article (PubMed ID: 1920349)
1. Structure-activity studies of antitumor agents based on pyrrolo[1,2-a]benzimidazoles: new reductive alkylating DNA cleaving agents.
Islam I; Skibo EB; Dorr RT; Alberts DS
J Med Chem; 1991 Oct; 34(10):2954-61. PubMed ID: 1920349
[TBL] [Abstract][Full Text] [Related]
2. A comparison of the cytotoxic and physical properties of aziridinyl quinone derivatives based on the pyrrolo[1,2-a]benzimidazole and pyrrolo[1,2-a]indole ring systems.
Boruah RC; Skibo EB
J Med Chem; 1994 May; 37(11):1625-31. PubMed ID: 8201596
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity studies of benzimidazole-based DNA-cleaving agents. Comparison of benzimidazole, pyrrolobenzimidazole, and tetrahydropyridobenzimidazole analogues.
Skibo EB; Islam I; Heileman MJ; Schulz WG
J Med Chem; 1994 Jan; 37(1):78-92. PubMed ID: 8289204
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolo[1,2-a]benzimidazole-based aziridinyl quinones. A new class of DNA cleaving agent exhibiting G and A base specificity.
Skibo EB; Schulz WG
J Med Chem; 1993 Oct; 36(21):3050-5. PubMed ID: 8230090
[TBL] [Abstract][Full Text] [Related]
5. Studies of pyrrolo[1,2-alpha]benzimidazolequinone DT-diaphorase substrate activity, topoisomerase II inhibition activity, and DNA reductive alkylation.
Skibo EB; Gordon S; Bess L; Boruah R; Heileman MJ
J Med Chem; 1997 Apr; 40(9):1327-39. PubMed ID: 9135030
[TBL] [Abstract][Full Text] [Related]
6. Chemistry of the pyrrolo[1,2-alpha]benzimidazole antitumor agents: influence of the 7-substituent on the ability to alkylate DNA and inhibit topoisomerase II.
Zhou R; Skibo EB
J Med Chem; 1996 Oct; 39(21):4321-31. PubMed ID: 8863809
[TBL] [Abstract][Full Text] [Related]
7. First synthesis of an aziridinyl fused pyrrolo[1,2-a]benzimidazole and toxicity evaluation towards normal and breast cancer cell lines.
Bonham S; O'Donovan L; Carty MP; Aldabbagh F
Org Biomol Chem; 2011 Oct; 9(19):6700-6. PubMed ID: 21808774
[TBL] [Abstract][Full Text] [Related]
8. Pyrrolobenzimidazoles linked to heterocycles and peptides. Design of DNA base pair specific phosphate hydrolyzing agents and novel cytotoxic agents.
Ghodousi A; Huang X; Cheng Z; Skibo EB
J Med Chem; 2004 Jan; 47(1):90-100. PubMed ID: 14695823
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of quinone-containing alkylating agents: DNA alkylation by aziridinylquinones.
Hargreaves RH; Hartley JA; Butler J
Front Biosci; 2000 Nov; 5():E172-80. PubMed ID: 11056081
[TBL] [Abstract][Full Text] [Related]
10. Synthesis of C8-linked pyrrolo[2,1-c][1,4]benzodiazepine-benzimidazole conjugates with remarkable DNA-binding affinity.
Kamal A; Ramulu P; Srinivas O; Ramesh G; Kumar PP
Bioorg Med Chem Lett; 2004 Sep; 14(18):4791-4. PubMed ID: 15324909
[TBL] [Abstract][Full Text] [Related]
11. Aziridinyl quinone antitumor agents based on indoles and cyclopent[b]indoles: structure-activity relationships for cytotoxicity and antitumor activity.
Skibo EB; Xing C; Dorr RT
J Med Chem; 2001 Oct; 44(22):3545-62. PubMed ID: 11606119
[TBL] [Abstract][Full Text] [Related]
12. Evidence for DNA phosphate backbone alkylation and cleavage by pyrrolo[1,2-a]benzimidazoles: small molecules capable of causing base-pair-specific phosphodiester bond hydrolysis.
Schulz WG; Nieman RA; Skibo EB
Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11854-8. PubMed ID: 8524862
[TBL] [Abstract][Full Text] [Related]
13. Triple molecular target approach to selective melanoma cytotoxicity.
Skibo EB; Jamil A; Austin B; Hansen D; Ghodousi A
Org Biomol Chem; 2010 Apr; 8(7):1577-87. PubMed ID: 20237668
[TBL] [Abstract][Full Text] [Related]
14. A novel synthetic DNA minor groove binder, MS-247: antitumor activity and cytotoxic mechanism.
Matsuba Y; Edatsugi H; Mita I; Matsunaga A; Nakanishi O
Cancer Chemother Pharmacol; 2000; 46(1):1-9. PubMed ID: 10912571
[TBL] [Abstract][Full Text] [Related]
15. Potent antitumor activity of MS-247, a novel DNA minor groove binder, evaluated by an in vitro and in vivo human cancer cell line panel.
Yamori T; Matsunaga A; Sato S; Yamazaki K; Komi A; Ishizu K; Mita I; Edatsugi H; Matsuba Y; Takezawa K; Nakanishi O; Kohno H; Nakajima Y; Komatsu H; Andoh T; Tsuruo T
Cancer Res; 1999 Aug; 59(16):4042-9. PubMed ID: 10463605
[TBL] [Abstract][Full Text] [Related]
16. Synthesis of 6-aziridinylbenzimidazole derivatives and their in vitro antitumor activities.
Ahn CM; Kim SK; Han JL
Arch Pharm Res; 1998 Oct; 21(5):599-609. PubMed ID: 9875502
[TBL] [Abstract][Full Text] [Related]
17. CBI-CDPBO1 and CBI-CDPBI1: CC-1065 analogs containing deep-seated modifications in the DNA binding subunit.
Boger DL; Yun W; Cai H; Han N
Bioorg Med Chem; 1995 Jun; 3(6):761-7. PubMed ID: 7582954
[TBL] [Abstract][Full Text] [Related]
18. Design of highly active analogues of the pyrrolo[1,2-a]benzimidazole antitumor agents.
Craigo WA; LeSueur BW; Skibo EB
J Med Chem; 1999 Aug; 42(17):3324-33. PubMed ID: 10464019
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and docking studies of novel antitumor benzimidazoles.
Omar MA; Shaker YM; Galal SA; Ali MM; Kerwin SM; Li J; Tokuda H; Ramadan RA; El Diwani HI
Bioorg Med Chem; 2012 Dec; 20(24):6989-7001. PubMed ID: 23123017
[TBL] [Abstract][Full Text] [Related]
20. Structure-activity relationships of antitumor thiazolo[3,4-a]benzimidazole derivatives.
Chimirri A; Grasso S; Montforte AM; Montforte P; Zappalà M; Carotti A
Farmaco; 1994 May; 49(5):337-44. PubMed ID: 8080616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
